Completed PHASE4 INTERVENTIONAL 2-arm NCT01917656

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes (LIRA-Ramadan™)

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2

Interventions liraglutide metformin sulphonylurea

Updated 8 times since 2017 Last updated: Jul 25, 2017 Started: Jan 9, 2014 Primary completion: Sep 1, 2014 Completion: Sep 4, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01917656, this PHASE4 trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Sep 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Ajman, United Arab Emirates , Algiers, Algeria , Bangalore, India , Beersheba, Israel , Beirut, Lebanon , Benoni, South Africa , Cheras, Malaysia , Constantine, Algeria , Dubai, United Arab Emirates and 23 more locations